MX368972B - Composiciones de glicoproteínas sialiladas y usos de estas. - Google Patents

Composiciones de glicoproteínas sialiladas y usos de estas.

Info

Publication number
MX368972B
MX368972B MX2016011416A MX2016011416A MX368972B MX 368972 B MX368972 B MX 368972B MX 2016011416 A MX2016011416 A MX 2016011416A MX 2016011416 A MX2016011416 A MX 2016011416A MX 368972 B MX368972 B MX 368972B
Authority
MX
Mexico
Prior art keywords
glycoprotein compositions
sialylated glycoprotein
sialylated
compositions
disorders
Prior art date
Application number
MX2016011416A
Other languages
English (en)
Spanish (es)
Other versions
MX2016011416A (es
Inventor
Steven Jungles
Morris Gabrielle
Grubb Jeff
Vellard Michael
D Kakkis Emil
Original Assignee
Ultragenyx Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ultragenyx Pharmaceutical Inc filed Critical Ultragenyx Pharmaceutical Inc
Publication of MX2016011416A publication Critical patent/MX2016011416A/es
Publication of MX368972B publication Critical patent/MX368972B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2468—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on beta-galactose-glycoside bonds, e.g. carrageenases (3.2.1.83; 3.2.1.157); beta-agarase (3.2.1.81)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01031—Beta-glucuronidase (3.2.1.31)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2016011416A 2014-03-05 2015-03-05 Composiciones de glicoproteínas sialiladas y usos de estas. MX368972B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461948421P 2014-03-05 2014-03-05
US201562114313P 2015-02-10 2015-02-10
PCT/US2015/018859 WO2015134696A1 (en) 2014-03-05 2015-03-05 Sialylated glycoprotein compositions and uses thereof

Publications (2)

Publication Number Publication Date
MX2016011416A MX2016011416A (es) 2016-12-02
MX368972B true MX368972B (es) 2019-10-23

Family

ID=54016314

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016011416A MX368972B (es) 2014-03-05 2015-03-05 Composiciones de glicoproteínas sialiladas y usos de estas.

Country Status (17)

Country Link
US (9) US9457067B2 (https=)
EP (1) EP3113781B1 (https=)
JP (1) JP6581590B2 (https=)
KR (1) KR102150481B1 (https=)
CN (1) CN106102749B (https=)
AU (1) AU2015227137B2 (https=)
BR (1) BR112016019893B1 (https=)
CA (1) CA2940318C (https=)
ES (1) ES2704923T3 (https=)
IL (1) IL247550B (https=)
MX (1) MX368972B (https=)
MY (1) MY188028A (https=)
PE (1) PE20161417A1 (https=)
PH (1) PH12016501658A1 (https=)
RU (1) RU2689119C2 (https=)
TW (1) TWI702049B (https=)
WO (1) WO2015134696A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20161417A1 (es) 2014-03-05 2017-01-22 Ultragenyx Pharmaceutical Inc Composiciones de glicoproteinas sialiladas y uso de estas
WO2019116259A1 (en) 2017-12-13 2019-06-20 3M Innovative Properties Company Water-reconstitutable culture medium resistant to liquefaction by microorganisms
TWI667252B (zh) * 2018-07-13 2019-08-01 中原大學 阿伐-選擇性唾液酸供體及其於製備唾液酸苷的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458574B1 (en) * 1996-09-12 2002-10-01 Transkaryotic Therapies, Inc. Treatment of a α-galactosidase a deficiency
CA2492267C (en) * 2002-07-15 2013-09-10 Immunex Corporation Methods and media for controlling sialylation of proteins produced by mammalian cells
US20060104968A1 (en) * 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
JP2008504008A (ja) * 2003-12-31 2008-02-14 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 改良された薬物動態を有するＦｃ−エリスロポエチン融合タンパク質
EP1818395A1 (en) * 2006-02-08 2007-08-15 Diatos Compositions and methods for treating lysosomal storage diseases
SI2073842T1 (sl) * 2006-09-10 2015-05-29 Glycotope Gmbh Uporaba človeških celic izvirajočih iz mieloične levkemije za izražanje protiteles
WO2008109677A2 (en) * 2007-03-06 2008-09-12 Saint Louis University Modified enzyme and treatment method
CN102482674B (zh) * 2010-02-08 2014-03-26 韩国科学技术院 制备具有高唾液酸含量的重组糖蛋白的方法
WO2012101671A1 (en) * 2011-01-25 2012-08-02 Jcr Pharmaceuticals Co., Ltd. Method for production of human recombinant iduronate 2-sulfatase
KR101457514B1 (ko) * 2011-11-21 2014-11-03 한국생명공학연구원 우렁쉥이(멍게) 유래의 시알산 전이효소 및 이를 이용한 시알화 복합당질 합성 방법
US10138474B2 (en) * 2012-08-17 2018-11-27 Research Foundation Of The City University Of New York Scavenger receptor uptake for fabry disease enzyme replacement therapy
PE20161417A1 (es) 2014-03-05 2017-01-22 Ultragenyx Pharmaceutical Inc Composiciones de glicoproteinas sialiladas y uso de estas

Also Published As

Publication number Publication date
CA2940318C (en) 2020-09-22
RU2016138790A (ru) 2018-04-09
US20260077025A1 (en) 2026-03-19
US20150366951A1 (en) 2015-12-24
AU2015227137A1 (en) 2016-09-15
TW201615210A (zh) 2016-05-01
IL247550A0 (en) 2016-11-30
US9457068B2 (en) 2016-10-04
AU2015227137B2 (en) 2019-06-06
JP6581590B2 (ja) 2019-09-25
RU2016138790A3 (https=) 2018-08-23
US20190054153A1 (en) 2019-02-21
CN106102749A (zh) 2016-11-09
CN106102749B (zh) 2019-07-12
BR112016019893A2 (pt) 2017-10-24
US20240245759A1 (en) 2024-07-25
US9937243B2 (en) 2018-04-10
US20160367646A1 (en) 2016-12-22
KR102150481B1 (ko) 2020-09-02
CA2940318A1 (en) 2015-09-11
US20200282028A1 (en) 2020-09-10
ES2704923T3 (es) 2019-03-20
BR112016019893B1 (pt) 2023-02-14
RU2689119C2 (ru) 2019-05-24
US9457067B2 (en) 2016-10-04
MY188028A (en) 2021-11-10
WO2015134696A1 (en) 2015-09-11
EP3113781B1 (en) 2018-11-21
US20220202915A1 (en) 2022-06-30
US20170326210A1 (en) 2017-11-16
US9687532B2 (en) 2017-06-27
TWI702049B (zh) 2020-08-21
KR20160127124A (ko) 2016-11-02
MX2016011416A (es) 2016-12-02
US20150250860A1 (en) 2015-09-10
IL247550B (en) 2020-10-29
PH12016501658A1 (en) 2016-10-03
EP3113781A4 (en) 2017-08-09
JP2017508455A (ja) 2017-03-30
PE20161417A1 (es) 2017-01-22
EP3113781A1 (en) 2017-01-11

Similar Documents

Publication Publication Date Title
BR112017000456A2 (pt) composições antivirais tópicas e métodos de uso das mesmas
PL3145522T3 (pl) Kombinacja, kompozycja i sposób podawania kombinacji lub kompozycji zwierzętom
MX385845B (es) Usos y composiciones de la flagelina
MX360041B (es) Composiciones y metodos para el cuidado personal.
MX395231B (es) Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de hígado graso, y uso de los mismos.
BR112016017112A2 (pt) Composições de apilimod e métodos de uso das mesmas
PH12017500836A1 (en) Transdermal formulations
EA201790461A1 (ru) Композиции внеклеточного матрикса
MX374385B (es) Apilimod para uso en el tratamiento de melanoma.
MX386055B (es) Uso de medicamentos para disminuir la evolución de la enfermedad de parkinson.
PH12018501279A1 (en) Compositions comprising 15-hepe and methods of using the same
MX2023010501A (es) Profarmacos de dantroleno y metodos de su uso.
MX390126B (es) Nuevas isoformas de tripsina y su uso.
MX379126B (es) Formulación de factor viii.
PH12016501434A1 (en) Compositions for use in the treatment of allergic conditions
IT201600130012A1 (it) Composizione per uso nel trattamento di disturbi dell'apparato uro-genitale
MX2016011416A (es) Composiciones de glicoproteinas sialiladas y usos de estas.
MX378868B (es) Sintesis de polioles polimericos en polioles insaturados, polioles polimericos y su uso.
ECSP18050673A (es) Formulaciones de giberelina en solución concentrada
MX383460B (es) Derivados peptidicos novedosos y sus usos.
MX385652B (es) Composicion heterofasica.
MX380683B (es) Lisobactina para su uso en el tratamiento de la mastitis bovina.
MY171137A (en) Thioguanine derivatives
DOP2015000290A (es) Benzoxazoles sustituidos
ITUA20161288A1 (it) Composizione per favorire la risalita degli spermatozoi nel canale cervico-vaginale umano.

Legal Events

Date Code Title Description
FG Grant or registration